Takeda (ADR) (TAK)
Develops prescription medicines across gastrointestinal disease, rare disease, plasma therapies, oncology, neuroscience, and vaccines.
Something off on this page? Send us feedback.
Sells prescription medicines led by ENTYVIO and immunoglobulin therapies across six global business areas. Operates as one reportable segment, with major commercial activity spanning the United States, Europe, Japan, China, and other markets.
Develops and markets prescription medicines across gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, vaccines, and other products. ENTYVIO is the largest product, while immunoglobulin brands form another major franchise.
Operates globally, with commercial activity across the United States, Europe, Japan, China, and other markets. Research, manufacturing, licensing, and specialized commercialization support a portfolio assembled through internal development and the Millennium, Nycomed, and Shire acquisitions.
Executes around established specialty franchises while preparing late-stage candidates for regulatory submission and launch. Revenue remains exposed to patent expiry, as VYVANSE's loss of exclusivity has reduced sales, and future product transitions depend on regulatory approvals and commercial execution. The group reports as one operating segment, and each NYSE ADS represents half of a Tokyo-listed ordinary share.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.35B · Total debt $31.37B · Total assets $99.45B · Shareholders' equity $47.99B
- Revenue
- $7.75B
- Operating income
- $1.28B
- Net income
- $718.7M
Reported in JPY, converted at the latest exchange rate
HistoryDividendAnnual yield
| Institutions | 3.30% | 104.85M ADS | |
|---|---|---|---|
| 387 holders · as of Jun 30, 2026 | |||
| Insiders | 0.09% | 2.75M ADS | |
| 14 holders · as of Sep 15, 2026 | |||
| Other | 96.61% | 3.07B ADS | |
| remainder | |||
3.18B ADS as of Sep 20, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Capital Research Global InvestorsInstitution | 0.61% | 19.30M ADS | as of Jun 30, 2026 |
FMR LLCInstitution | 0.30% | 9.60M ADS | as of Jun 30, 2026 |
Morgan StanleyInstitution | 0.22% | 6.99M ADS | as of Jun 30, 2026 |
Adage Capital Partners GP, L.L.C.Institution | 0.19% | 6.05M ADS | as of Jun 30, 2026 |
Goldman Sachs Group IncInstitution | 0.16% | 5.13M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 14, 2026 | Lauren Rusckowski Duprey | officer: Chief Transformation Officer | −34,535 | $18.54 |
| Sep 2, 2026 | Andrew Stewart Plump | director, officer: President, R&D | −116,191 | $18.49 |
| Aug 19, 2026 | Andrew Stewart Plump | director, officer: President, R&D | −19,651 | $18.49 |
| Aug 18, 2026 | Nicola Deidre Petal Greenway | officer: Chief Human Resources Officer | −12,980 | $18.11 |
| Aug 10, 2026 | Rhonda Janice Pacheco | officer: President, U.S. Business Unit | −16,901 | $17.10 |
- AbbVie
Leading IBD overlap across Crohn's disease and ulcerative colitis
- Grifols (ADR)
Direct plasma-medicine rival in immunoglobulin and albumin
- Johnson & Johnson
Biologic competition in Crohn's disease and ulcerative colitis
- Eli Lilly
IL-23 competition in ulcerative colitis and Crohn's disease
- Pfizer
Focused overlap in ulcerative colitis and hemophilia prophylaxis
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Takeda (ADR) | $19.01 | +0.61% | $60.11B | 52.5 | 60.1 | 2.0 | +4.2% |
| AbbVie | $265.14 | +0.25% | $467.37B | 74.5 | 17.4 | 7.3 | +10.2% |
| Grifols (ADR) | $7.43 | +0.88% | $6.23B | 9.6 | — | 0.7 | −1.8% |
| Johnson & Johnson | $268.35 | −0.42% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| Eli Lilly | $1,172.69 | +0.67% | $1.10T | 39.1 | 28.7 | 13.8 | +47.7% |
| Pfizer | $27.88 | +0.50% | $158.10B | 36.7 | 10.0 | 2.5 | +2.6% |
| Median | 36.7 | 20.0 | 6.6 | +6.6% |